Rola firm farmaceutycznych w udostępnianiu tanich leków dobrej jakości w krajach rozwijających się

• Authors: Marta Soniewicka

Title variants

EN

The Role of Pharmaceutical Companies in Making Accessible and Affordable Medicines of Good Quality in Developing Countries

• Languages of publication: PL

Abstracts

EN

Using the example of a global pharmaceutical industry, I examine the role of private companies in fulfilling social aims. I address the problem of aid in the context of availability of affordable and safe medicines in developing countries, which is one aspect of fulfilling the right to health. Are the mechanisms of free market and philanthropic actions of pharmaceutical companies sufficient to guarantee essential medicines to the most vulnerable inhabitants of the world? Are international pharmaceutical concerns obliged to guarantee human rights only or to deliver human rights, in particular the right to health, as well? The article presents the conflict of interests between profit-driven pharmaceutical industry and ethically-driven public health, which can be fully addressed only by certain legal regulations. The thesis argued in the article is that free market itself cannot solve its failures (such as undersupply of innovations, undersupply of non-beneficial medicines, monopolistic policies and pricing); to solve the problem it is required to set up public institutions and legal regulations of both local and global scope. Neither free market, nor benevolent aid actions of pharmaceutical companies can address the problem of health care in developing countries, where the lack of medicines is a small aspect of a much broader and intricate problem of poverty and the weakness of state institutions which are not responsive to the basic needs of its citizens.

Keywords

EN

pharmaceutical industry; Pharma; medicines; drugs; right to health; affordable medicines; clinical trials; intellectual property rights; free trade; global aid; global justice; multinational corporations; globally neglected diseases; healthcare; free market

• Publisher: Instytut Filozofii i Socjologii Polskiej Akademii Nauk / Akademia Leona Koźmińskiego
• Journal: Prakseologia
• Year: 2012
• Issue: 153
• Pages: 315-336

Contributors

author

Marta Soniewicka

• Uniwersytet Jagielloński Katedra Filozofii Prawa i Etyki Prawniczej, ul. Bracka 12,31-005 Kraków

References

• Annas G.J. 2004. American Bioethics. Crossing Human Rights and Health Law Boundaries. Oxford: Oxford University Press.
• Annas G.J. 2010. Worst Case Bioethics. Death, Disaster, and Public Health. Oxford: Oxford University Press.
• Arendt H. 1999. O przemocy. Nieposłuszeństwo obywatelskie. Przeł. A. Łagodzka, W. Madej. Warszawa: Fundacja ALETHEIA.
• Buncombe A., Lakhani N. 2011. Without consent: how drugs companies exploit Indian ‘guinea pigs’. „The Independent”, 14 listopada 2011. (dostępne online: http://www.independent.co.uk/news/world/asia/without-consent-how-drugs-companies-exploit-indianguinea-pigs-6261919.html).
• Cook-Deegan R., T. Dedeurwaerdere. 2006. The Science Commons in Life Science Research: Structure, Function, and Value of Access to Genetic Diversity. „International Social Science Journal”, 58: 299–317.
• Hira A. 2009. The political economy of the global pharmaceutical industry. Why the poor lack access to medicine and what might be done about it. „International Journal of Development”, 8: 84–101.
• Holland S., Bátiz-Lazo B. 2004. The Global Pharmaceutical Industry. „General Economics and Teaching” 0405002(EconWPA): 1–24.
• IMS Health Market Prognosis. Marzec 2011 (dane na rok 2010). NJ. (dostępne online: www.theimsinstitute.org ).
• Kuper A. 2005. Redistributing Responsibilities – The UN Global Compact with Corporations. A. Follesdal, T. Pogge (eds.). Real World Justice. Grounds, Principles, Human Rights, and Social Institutions. Dordrecht: Springer.
• Nozick R. 1999. Anarchia, państwo, utopia. Przeł. M. Maciejko i M. Szczubiałka. Warszawa: Fundacja ALETHEIA.
• O’Neill O. 2005. Agents of Justice. A. Kuper (red.). Global Responsibilities: Who Must Deliver on Human Rights?. New York – London: Routledge.
• Osiatyński W. 2011. Prawa człowieka i ich granice. Przeł. S. Kowalski. Kraków: Znak.
• OXFAM. 2011. Eye on the Ball. Medicine regulation – not IP enforcement – can Best deliver quality medicines. „Oxfam Briefing Paper”, 2 lutego 2011 (dostępne online: www.oxfam.org).
• Ozierański P., McKee M., King L. 2011. Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? „Health Economics, Policy and Law”, 7: 175–195.
• Petryna A. 2009. When Experiments Travel. Clinical Trials and the Global Search for Human Subjects. Princeton and Oxford: Princeton University Press.
• Pogge T. 2007. Could Globalization Be Good For World Health? „Global Justice: Theory Practice Rhetoric”, 1:1–10.
• Sachs J.D. et al. 2000. Macroeconomics and Health Investing in Health for Economic Development. WHO: Geneva.
• Silverstein K. 1999. Millions for Viagra, Pennies for Diseases for the Poor. „The Nation”, 19 lipca. (dostępne online http://www.thenation.com/article/millions-viagra-pennies-dis- eases-poor).
• Singer P. 2010. Życie które możesz ocalić. Przeł. E. de Lazari. Warszawa: Wydawnictwo Czarna Owca.
• Stiglitz J. 2004. Globalizacja. Przeł. H. Siembierowicz. Warszawa: PWN.
• Stiglitz J. 2006. Scrooge and Intellectual Property Rights. „British Medical Journal” 333: 1279.
• Talmud. 2012. Mas. Sanhedrin (Court of Justice). Soncino Babylonian Talmud. Przeł. Canon Danby http://www.halakhah.com
• UNDP (United Nations Development Programme). 2005. Human Development Report 2005. New York.
• Weber L. J. 2003. Pharmaceutical Industry, w: S. G. Post (red.), Encyclopedia of Bioethics, t. 4. MacMillan Reference Books.
• Werner K., Weiss H. 2009. Czarna Lista Firm. Intrygi światowych koncernów. Przeł. JE. Franek. Wydawnictwo Hidari.